A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

NCT02146313 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Neoplasms
Ovarian Neoplasms

Interventions

DRUG: DMUC4064A

Sponsor

Genentech, Inc.